kan jeg kobe haridra for piles

generisk haridra plant

1. I quit sugar period (that means fruit, too). Google “The Candida Diet”.
2. I drank the teas and took the herbs mentioned in this blog and other blogs: American Saffron, Slippery Elm Bark, Red Ginseng.
3. I quit Caffeine and Alcohol. Hard! However, this was much less painful by taking L-Theanine daily. I took it mornings to remove anxiety and at night to go out on dates and socialize and still feel relaxed without drinking. The brands I tried:

-Lucid Lumin SunTheanine.
-Whole Foods SunTheanine.
-Sports Nutrition SunTheanine

L-Theanine does not do a thing for psoriasis. However, it does wonders for your mental state and sense of calmness and wellness while going through the healing process.

4. I did a 15 day raw juice fast (I did do some sugar here: Carrots and Apples in the Juice). OK it only made it 14 days but it still helped.

5. Three Colon Hydro-therapy Sessions. Not a fan of these but after seeing what comes out I will probably do this annually from here on out.

6. For my junk: The junk seemed to be the slowest responder to all the above work I was doing. I was getting frustrated as I was newly single and with strange new patches of psoriasis on my unit that I did not want to explain. The other patches were clearing up but not the junk. So I took a chance and bought – off ebay – the following UVB Wand: “Kernel KN-4003B UV Photo Therapy”

I used it 3 to five times a week. Pointing that thing at my junk for over 3 minutes would burn my poor unit. So do NOT keep this wand pointed at any part of your skin for more than a few minutes. Wear the protective glasses that come with it. When you first start out only use the wand for 1 minute or even less, and work up to 3 (ish) minutes over the first week. I once went 3 minutes and 30 seconds but it was too painful the next day – (UVBs) are designed to burn.

Do all the above and you will be clear in a month or two (or three).

I will probably not be back here because, well, it’s clear now! But this blog post and comments section was read by me a few times since July so I appreciate it Jack, and all the other commenters, for providing tips and hope on path to recovery.

You can do this. You got this. Onward and upward people.

Awesome stuff Wayne and super dedication. I’m also a fan of l-theanine, as well as sulbutiamine, for their calming affects. Thanks for coming back and sharing your success!

i deleted sugar caffeine fruits and bread meat alcohol for 50 days it has improved became pink faded but still it shines when i have sex. please where can we find l theanine is this available as tablets?

Thanks for this post, Jack, because I have never known another guy who had this like I do and I have told a couple friends but they can’t really know what it is like (one said it was just ‘moss on the tree’.) So it means a lot just to know others have to face this.

I have found that cotton boxers are best. Any tight underwear, even if cotton, makes it worse when it flares up. I first got it on the penis & sac about 20 years ago. It eased up but came back, not always in the same place. Now it is in the same places but flares up and winds down. I can’t figure out a pattern, but trying out different soaps and avoiding others has helped. Worst place for cracking in painful way is the angle where wang tends to hang regularly. Also have found using lotion that contains dead sea salt has helped. Avoid beating off if I must (short a time as possible) or, try different approaches.

Hey everybody, use Protopic 0.1% ointment for psoriasis on the penis. It takes about a week to clear it up, two if it’s on the head of the penis, but it It clears it up every single time. It works really well in thin skin areas.

Has any tried putting zinc oxide cream on it? The kind they sell for diaper rash.

What is the result please

Hi, I’ve this problem for 8/9 years now, I did struggle to treat it at first, I was prescribed creams way too strong by a US based GP but now after a visit to a UK doctor lady, she asked me to use doublebase dayleve gel as a twice daily precaution and after using the gel to medicate it with curatoderm, it clears in a couple of days, my best advice so far.

I have had psoriasis on my penis for about 20 years and have never looked for information on the internet about it before. Thank you for this blog.
I am able to control the surface irritations pretty well. However, I feel it “deeper”. By this I mean that I feel like my sensitivity has been diminished and that the psoriasis is almost lurking under the skin. As a consequence it takes me longer to orgasm. Does this description sound familiar to anyone?

Masterbate less, eat healthier, drink less alcohol.
Use organic cold pressed coconut oil for a moisturizer or even to rub one out.
For the occasional bad flare up, try protopic… But only when necessary.

This is what I found most useful.

Hey guys I have been dealing with this issue for 7 years now. It also reaches my butt hole curing fishers OMG the pain. Now after this summer it has gotten worse it has now attacked my sack as well super itchy and driving me crazy. The wife can’t even begin to imagine what I’m going through and thinks I blow it out of proportion. Any helpful tips on diet of creams I may have not tried. I normally managed with the pain using steroid creams but now the spread to my sack has just gone beyond what I can deal with it feels like there’s no hope.

I’ve suffered from mild to medium penile psoriasis for about 15 years. I’ve largely got the situation under control – but I’m managing the problem rather than curing it. Here’s what I’ve learned and what works for me:
– Take care of your penis before it’s too late! For years I dry masturbated, washed under the foreskin with soaps and didn’t rinse after sex/masturbation.
– Get the diagnosis right. For a number of years I thought I was suffering from thrush and tried to treat it with anti-fungal creams. What’s added confusion to my situation is that I do also occasionally get jock itch around my groin, which is a fungal infection.
– Don’t wash the head with soap, just use tepid water. I think one of the reasons why psoriasis occurs is an imbalance in the penis’ natural ecosystem of bacteria and therefore its ability to ‘take care of itself’. Soap kills the good bacteria as well as the bad bacteria. I’ve also surmised that my mistaken use of anti-fungal creams probably didn’t help my ecosystem.
– I make sure that I shake out all lose drops after urination and use toilet paper to make sure there’s no dripping, as urine seems to agitate the situation.
– I moisturise regularly with this – http://www.neutrogena.co.uk/product/hand-cream/norwegian-formula-unscented-hand-cream. I’ve tried a few moisturisers and this one works the best for me. I moisturise after urination and ejaculation (once clean).
– If I get a flair up I will use 1% hydrocortisone cream to bring it back under control. I’m pretty paranoid about using this due to skin thinning so I never use it more than 3 days in a row and no more than twice a day.
– After applying the hydrocortisone it seems to be particularly effective if I apply the Neutrogena cream about 3 hours afterwards – i.e. I give the hydrocortisone ‘something to work with’.
– I find it flairs up most after sex or masturbation, but only if ejaculate. I have a theory that some sort of (protein?) allergy might be at play as pre-cum also seems to affect the psoriasis. My other theory is that it’s the heat and/or blood that flows to the area.
– I’ve significantly reduced the amount I masturbate, but when I do I use this as lubrication http://www.waitrose.com/shop/ProductView-10317-10001-2841-Waitrose+baby+bottom+butter. Before I discovered the Neutrogena hand cream, I used this as my primary moisturiser. It doesn’t absorb as well as the hand cream, but that’s a benefit in this context
– After ejaculatory sex or masturbation I rinse the area thoroughly with tepid water – making sure that any ‘aftermath’ is also washed away. It’s then essential to apply the Neutrogena cream. If I know I’m going to have sex again the next day and I need to ‘look my best’, I will sometimes apply hydrocortisone instead of the Neutrogena
– Using a condom during sex reduces the post-sex reaction. I use latex-free Skyn condoms
– Rounding all this up, factors that seem to contribute to flair ups are – heat, friction, urine, semen, soaps and also excessive alcohol
– All the above comes with a massive disclaimer – I am not a doctor nor dermatologist nor have I ever been to a doctor or dermatologist about my psoriasis. Stupid I know, but hey I’m a bloke.

@Jon – also to add to my second point about diagnosis – be careful as steroid creams make fungal infections worse.

Patienter med eksem har ved kliniske forsøg opnået store forbedringer i deres sygdomsbillede ved at tage tilskud af GLA. Andreassi og hans kolleger ved University of Italy satte sig for at påvise effekten af at anvende GLA fra boragoolie til behandling af eksem. Deres resultater blev offentliggjort i Journal of International Medical Research i 1997.

I alt 60 patienter (fordelt på 30 mænd og 30 kvinder), der alle led af eksem, deltog i undersøgelsen, som strakte sig over 12 uger. Halvdelen af forsøgspersonerne fik 274 mg GLA to gange dagligt (i form af 1-2 1.000 mg bløde kapsler indeholdende boragoolie to gange dagligt), mens den anden halvdel fik et placebopræparat. Symptomer blev vurderet såvel af en dermatolog som af forsøgsdeltagerne selv hver 4. uge. Hos de patienter, der fik GLA-tilskuddet, kunne man notere gradvise og betydelige forbedringer i kløe, inflammation, dannelse af blæner og omfanget af væskende eksemområder sammenlignet med kontrolgruppen. Hos nogle lå denne forbedring på helt op til 90% efter behandling med boragoolie.

De patienter, som fik GLA-tilskuddet, var i stand til at nedsætte deres forbrug af antihistamin og steroidpræparater med 73%, antibiotika med 80% og steroide hudpræparater med 50%. Forskerne konkluderede, at GLA-tilskud i form af boragoolie er effektivt til behandling af eksem, og at de største forbedringer indtræffer efter 6-12 uger. Boragoolie har ingen af de bivirkninger, der normalt ses ved antihistamin-behandling.

Boragoolie: forbedring af effektiviteten
Også andre undersøgelser har påvist boragooliens virkning, uskadelighed og anvendelighed over for eksemtilstande. 28 japanske eksempatienter blev behandlet med boragoolie i en dosis på 180 mg pr. dag i henholdsvis 4, 8, 12 og 16 uger. Boragoolietilskuddet reducerede omfanget af patienternes symptomer i stigende grad, jo længere tid behandlingen stod på. Efter henholdsvis 8 og 12 ugers behandling kunne forskerne notere sig en mindskelse på 52,7% og 63,2% i omfanget af symptomerne. Den største fremgang kunne ses hos de patienter, som havde de mest udtalte symptomer (kløe, skællet hud og rødt udslæt).

Man kunne ikke påvise bivirkninger af betydning ved boragooliebehandlingen. Ifølge forskernes konklusion tyder deres resultater på, at boragoolie er et effektivt og uskadeligt middel til behandling af eksem i kombination med traditionelle lægemidler.

Boragoolie beskytter moden hud
Ifølge resultater, som blev offentliggjort i Archives of Gerontology and Geriatrics i 2002, har forskere undersøgt virkningen af boragoolie-tilskud på 29 sunde, ældre personer med henblik på at slå fast, hvordan olien indvirker på hudens "barriere"-funktion, dens indhold af vand og dens fedtsyrestofskifte. Undersøgelsens deltagere fik en daglig dosis på enten 360 eller 720 mg GLA (2-3 bløde kapsler med 1.000 mg boragoolie i hver) i to måneder. Hudens barrierefunktion forbedredes med 10,8%, væsketabet gennem huden blev betydeligt reduceret, og væskeindholdet i stratum corneum (det yderste hudlag) øgedes en lille smule. 34% af deltagerne led af kløe inden behandlingen, men ingen meldte om disse symptomer efter behandlingens afslutning. En øget mængde GLA og DGLA (et GLA-derivat) fra boragoolie kunne spores i cellemembranerne samtidig med, at man kunne påvise en tilsvarende nedgang i mængden af mættede, enkeltumættede og omega-9 fedtsyrer.

Denne forøgelse af hudens evne til at holde på væsken kan desuden være medvirkende til at modgå den forringelse af hudens evne til at fungere som barriere mod mikroorganismer, som sker ved ældning og som følge af, at man kradser på hudområder med kløe. Som undersøgelsen viser, kan boragoolie modvirke den kløe, som hyppigt forekommer hos raske, ældre personer - selv personer, der ikke lider af nogen form for hudsygdom. Man mener derfor, at hvis tilskud af boragoolie kan fjerne kløen, vil der ikke opstå sår som følge af kradsen - og dermed vil hudens barrierefunktion forblive intakt.

hvor kan jeg kobe haridra ganapati

During the placebo-controlled portion across the 3 clinical trials up to Week 16, the proportion of patients who experienced at least 1 serious adverse reaction (SAE; defined as resulting in death, life threatening, requires hospitalization, or persistent or significant disability/incapacity) was 0.5% in the 3 mg/kg REMICADE group, 1.9% in the placebo group, and 1.6% in the 5 mg/kg REMICADE group.

Among patients in the 2 Phase 3 studies, 12.4% of patients receiving REMICADE 5 mg/kg every 8 weeks through 1 year of maintenance treatment experienced at least 1 SAE in Study I. In Study II, 4.1% and 4.7% of patients receiving REMICADE 3 mg/kg and 5 mg/kg every 8 weeks, respectively, through 1 year of maintenance treatment experienced at least 1 SAE.

One death due to bacterial sepsis occurred 25 days after the second infusion of 5 mg/kg REMICADE. Serious infections included sepsis, and abscesses. In Study I, 2.7% of patients receiving REMICADE 5 mg/kg every 8 weeks through 1 year of maintenance treatment experienced at least 1 serious infection. In Study II, 1.0% and 1.3% of patients receiving REMICADE 3 mg/kg and 5 mg/kg, respectively, through 1 year of treatment experienced at least 1 serious infection. The most common serious infection (requiring hospitalization) was abscess (skin, throat, and peri-rectal) reported by 5 (0.7%) patients in the 5 mg/kg REMICADE group. Two active cases of tuberculosis were reported: 6 weeks and 34 weeks after starting REMICADE.

In the placebo-controlled portion of the psoriasis studies, 7 of 1123 patients who received REMICADE at any dose were diagnosed with at least one NMSC compared to 0 of 334 patients who received placebo.

In the psoriasis studies, 1% (15/1373) of patients experienced serum sickness or a combination of arthralgia and/or myalgia with fever, and/or rash, usually early in the treatment course. Of these patients, 6 required hospitalization due to fever, severe myalgia, arthralgia, swollen joints, and immobility.

Safety data are available from 4779 REMICADE-treated adult patients, including 1304 with rheumatoid arthritis, 1106 with Crohn’s disease, 484 with ulcerative colitis, 202 with ankylosing spondylitis, 293 with psoriatic arthritis, 1373 with plaque psoriasis and 17 with other conditions. [For information on other adverse reactions in pediatric patients, see ADVERSE REACTIONS]. Adverse reactions reported in ≥5% of all patients with rheumatoid arthritis receiving 4 or more infusions are in Table 2. The types and frequencies of adverse reactions observed were similar in REMICADE-treated rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and Crohn’s disease patients except for abdominal pain, which occurred in 26% of REMICADE-treated patients with Crohn’s disease. In the Crohn’s disease studies, there were insufficient numbers and duration of follow-up for patients who never received REMICADE to provide meaningful comparisons.

Table 2: Adverse reactions occurring in 5% or more of patients receiving 4 or more infusions for rheumatoid arthritis

The most common serious adverse reactions observed in clinical trials were infections [see Clinical Trials Experience]. Other serious, medically relevant adverse reactions ≥0.2% or clinically significant adverse reactions by body system were as follows:

  • Body as a whole: allergic reaction, edema
  • Blood:pancytopenia
  • Cardiovascular: hypotension
  • Gastrointestinal: constipation, intestinal obstruction
  • Central and Peripheral Nervous: dizziness
  • Heart Rate and Rhythm:bradycardia
  • Liver and Biliary:hepatitis
  • Metabolic and Nutritional: dehydration
  • Platelet, Bleeding and Clotting:thrombocytopenia
  • Neoplasms: lymphoma
  • Red Blood Cell:anemia, hemolytic anemia
  • Resistance Mechanism: cellulitis, sepsis, serum sickness, sarcoidosis
  • Respiratory: lower respiratory tract infection (including pneumonia), pleurisy, pulmonary edema
  • Skin and Appendages: increased sweating
  • Vascular (Extracardiac):thrombophlebitis
  • White Cell and Reticuloendothelial:leukopenia, lymphadenopathy

There were some differences in the adverse reactions observed in the pediatric patients receiving REMICADE compared to those observed in adults with Crohn’s disease. These differences are discussed in the following paragraphs.

The following adverse reactions were reported more commonly in 103 randomized pediatric Crohn’s disease patients administered 5 mg/kg REMICADE through 54 weeks than in 385 adult Crohn’s disease patients receiving a similar treatment regimen: anemia (11%), leukopenia (9%), flushing (9%), viral infection (8%), neutropenia (7%), bone fracture (7%), bacterial infection (6%), and respiratory tract allergic reaction (6%).

Infections were reported in 56% of randomized pediatric patients in Study Peds Crohn’s and in 50% of adult patients in Study Crohn’s I. In Study Peds Crohn’s, infections were reported more frequently for patients who received every 8-week as opposed to every 12-week infusions (74% and 38%, respectively), while serious infections were reported for 3 patients in the every 8-week and 4 patients in the every 12-week maintenance treatment group. The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess. Pneumonia was reported for 3 patients, (2 in the every 8-week and 1 in the every 12-week maintenance treatment groups). Herpes zoster was reported for 2 patients in the every 8-week maintenance treatment group.

In Study Peds Crohn’s, 18% of randomized patients experienced 1 or more infusion reactions, with no notable difference between treatment groups. Of the 112 patients in Study Peds Crohn’s, there were no serious infusion reactions, and 2 patients had non-serious anaphylactoid reactions.

In Study Peds Crohn’s, in which all patients received stable doses of 6-MP, AZA, or MTX, excluding inconclusive samples, 3 of 24 patients had antibodies to infliximab. Although 105 patients were tested for antibodies to infliximab, 81 patients were classified as inconclusive because they could not be ruled as negative due to assay interference by the presence of infliximab in the sample.

Elevations of ALT up to 3 times the upper limit of normal (ULN) were seen in 18% of pediatric patients in Crohn’s disease clinical trials; 4% had ALT elevations.3 x ULN, and 1% had elevations ≥5 x ULN. (Median follow-up was 53 weeks.)

Overall, the adverse reactions reported in the pediatric ulcerative colitis trial and adult ulcerative colitis (Study UC I and Study UC II) studies were generally consistent. In a pediatric UC trial, the most common adverse reactions were upper respiratory tract infection, pharyngitis, abdominal pain, fever, and headache.

Infections were reported in 31 (52%) of 60 treated patients in the pediatric UC trial and 22 (37%) required oral or parenteral antimicrobial treatment. The proportion of patients with infections in the pediatric UC trial was similar to that in the pediatric Crohn’s disease study (Study Peds Crohn’s) but higher than the proportion in the adults’ ulcerative colitis studies (Study UC I and Study UC II). The overall incidence of infections in the pediatric UC trial was 13/22 (59%) in the every 8 week maintenance treatment group. Upper respiratory tract infection (7/60 [12%]) and pharyngitis (5/60 [8%]) were the most frequently reported respiratory system infections. Serious infections were reported in 12% (7/60) of all treated patients.

In the pediatric UC trial, 58 patients were evaluated for antibodies to infliximab using the EIA as well as the drug-tolerant ECLIA. With the EIA, 4 of 58 (7%) patients had antibodies to infliximab. With the ECLIA, 30 of 58 (52%) patients had antibodies to infliximab [see Clinical Trials Experience, Immunogenicity]. The higher incidence of antibodies to infliximab by the ECLIA method was due to the 60-fold higher sensitivity compared to the EIA method. While EIA-positive patients generally had undetectable trough infliximab concentrations, ECLIA-positive patients could have detectable trough concentrations of infliximab because the ECLIA assay is more sensitive and drug-tolerant.

Elevations of ALT up to 3 times the upper limit of normal (ULN) were seen in 17% (10/60) of pediatric patients in the pediatric UC trial; 7% (4/60) had ALT elevations ≥3 x ULN, and 2% (1/60) had elevations ≥5 x ULN (median follow-up was 49 weeks).

Overall, 8 of 60 (13%) treated patients experienced one or more infusion reactions, including 4 of 22 (18%) patients in the every 8-week treatment maintenance group. No serious infusion reactions were reported.

In the pediatric UC trial, 45 patients were in the 12 to 17 year age group and 15 in the 6 to 11 year age group. The numbers of patients in each subgroup are too small to make any definitive conclusions about the effect of age on safety events. There were higher proportions of patients with serious adverse events (40% vs. 18%) and discontinuation due to adverse events (40% vs. 16%) in the younger age group than in the older age group. While the proportion of patients with infections was also higher in the younger age group (60% vs. 49%), for serious infections, the proportions were similar in the two age groups (13% in the 6 to 11 year age group vs. 11% in the 12 to 17 year age group). Overall proportions of adverse reactions, including infusion reactions, were similar between the 6 to 11 and 12 to 17 year age groups (13%).

Adverse reactions have been identified during post approval use of REMICADE in adult and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following adverse reactions, some with fatal outcome, have been reported during post-approval use of REMICADE: neutropenia [see WARNINGS AND PRECAUTIONS], agranulocytosis (including infants exposed in utero to infliximab), interstitial lung disease (including pulmonary fibrosis/interstitial pneumonitis and rapidly progressive disease), idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, pericardial effusion, systemic and cutaneous vasculitis, erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders (such as Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy), new onset and worsening psoriasis (all subtypes including pustular, primarily palmoplantar), transverse myelitis, and neuropathies (additional neurologic reactions have also been observed) [see WARNINGS AND PRECAUTIONS], acute liver failure, jaundice, hepatitis, and cholestasis [see WARNINGS AND PRECAUTIONS], serious infections [see WARNINGS AND PRECAUTIONS], malignancies, including melanoma, Merkel cell carcinoma, and cervical cancer [see WARNINGS AND PRECAUTIONS] and vaccine breakthrough infection including bovine tuberculosis (disseminated BCG infection) following vaccination in an infant exposed in utero to infliximab [see WARNINGS AND PRECAUTIONS].

In post-marketing experience, cases of anaphylactic reactions, including laryngeal/pharyngeal edema and severe bronchospasm, and seizure have been associated with REMICADE administration.

Cases of transient visual loss have been reported in association with REMICADE during or within 2 hours of infusion. Cerebrovascular accidents, myocardial ischemia/infarction (some fatal), and arrhythmia occurring within 24 hours of initiation of infusion have also been reported [see WARNINGS AND PRECAUTIONS].

The following serious adverse reactions have been reported in the post-marketing experience in children: infections (some fatal) including opportunistic infections and tuberculosis, infusion reactions, and hypersensitivity reactions.

Serious adverse reactions in the post-marketing experience with REMICADE in the pediatric population have also included malignancies, including hepatosplenic T-cell lymphomas [see BOX WARNING and WARNINGS AND PRECAUTIONS], transient hepatic enzyme abnormalities, lupus-like syndromes, and the development of autoantibodies.

Read the entire FDA prescribing information for Remicade (Infliximab)

En rigtig ernæring er alfa og omega for psoriasisramte, og der-for er denne bog vigtig for mennesker med psoriasis og deres familie. Den indeholder en grundigt beskrevet ernæringstera-peutisk handlingsplan og baggrunden for denne. Hvis man skal være vedholdende med en kost, der er anderledes end den sæd-vanlige, er det vigtigt at forstå hvorfor. Ellers lykkes det ikke. Principperne kan enhver læser have glæde af at læse om, ikke kun mennesker med psoriasis. Der er gode afsnit om ernæ-ringsmæssige mangler, om nedsat fordøjelsesfunktion og dårlig tarmflora, om overfølsomhed, nedsat afgiftningsevne, stress og ubalancer. Alt med gode forklaringer på, hvordan den normale og sunde fordøjelse fungerer, og hvordan man med naturlige midler kan bevare den.

Når man har psoriasis, vil hudcellerne i de tykke psoriasispletter dannes meget hurtigere end celler i normal hud. De skubbes hurtigere udefter og afstødes som sammenhængende skællag. En nydannet hudcelle er kun 4-8 dage om at bevæge sig fra de inderste hudlag til overfladen af huden, hvis man har psoriasis. Normalt tager det 28 dage. Mange bruger op til 3 timer hver dag på at smøre sig ind i forskellige cremer og salver. Det er efter min mening kun symptomundertrykkende behandling, der ikke gør noget ved årsagen til sygdommen, og at nogen bliver be-handlet med cellegifte, er som at skyde gråspurve med kanoner. Hvis lampen for olietryk i vores biler lyser, så klistrer vi da ikke pæren til, så vi ikke kan se advarslen, og kører videre. Nej! Vi skynder os at fylde ny olie på, så motoren ikke brænder sam-men. Det er efter min mening meget mere fornuftigt at opbygge cellerne og deres funktioner med god mad, vitaminer, mineraler og livsvigtige fedtsyrer, samtidig med at kroppens forskelligar-tede funktioner normaliseres.

– Forord af læge og sundhedskonsulent Carsten Vagn-Hansen

Af Ernæringsterapeut Marianne Fjordgård

haridra mg

Harding A. Extent of psoriasis tied to risk of comorbidities. Reuters Health Information. August 15, 2013. [Full Text].

Yeung H, Takeshita J, Mehta NN, et al. Psoriasis Severity and the Prevalence of Major Medical Comorbidity: A Population-Based Study. JAMA Dermatol. 2013 Aug 7. [Medline].

Patel RV, Shelling ML, Prodanovich S, Federman DG, Kirsner RS. Psoriasis and vascular disease-risk factors and outcomes: a systematic review of the literature. J Gen Intern Med. 2011 Sep. 26(9):1036-49. [Medline].

Li WQ, Han JL, Manson JE, Rimm EB, Rexrode KM, Curhan GC, et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol. 2012 Apr. 166(4):811-8. [Medline].

Henderson D. Psoriasis severity linked to uncontrolled hypertension. Medscape Medical News. October 27, 2014. [Full Text].

Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ, et al. Effect of Psoriasis Severity on Hypertension Control: A Population-Based Study in the United Kingdom. JAMA Dermatol. 2014 Oct 15. [Medline].

Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ. 2013 Oct 15. 347:f5961. [Medline].

Laidman J. Moderate and Severe Psoriasis Linked to Higher Kidney Risks. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/812730. Accessed: October 21, 2013.

Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010 Aug. 146(8):891-5. [Medline]. [Full Text].

Oostveen AM, de Jager ME, van de Kerkhof PC, Donders AR, de Jong EM, Seyger MM. The influence of treatments in daily clinical practice on the Children's Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. Br J Dermatol. 2012 May 23. [Medline].

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, et al. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol. 2012 Mar 9. [Medline].

Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003 Aug. 49(2):271-5. [Medline].

Sampogna F, Tabolli S, Soderfeldt B, Axtelius B, Aparo U, Abeni D. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006 May. 154(5):844-9. [Medline].

Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014 Nov. 171(5):1123-8. [Medline].

Moadel K, Perry HD, Donnenfeld ED, Zagelbaum B, Ingraham HJ. Psoriatic corneal abscess. Am J Ophthalmol. 1995 Jun. 119(6):800-1. [Medline].

Durrani K, Foster CS. Psoriatic uveitis: a distinct clinical entity?. Am J Ophthalmol. 2005 Jan. 139(1):106-11. [Medline].

Takahashi H, Sugita S, Shimizu N, Mochizuki M. A high viral load of Epstein-Barr virus DNA in ocular fluids in an HLA-B27-negative acute anterior uveitis patient with psoriasis. Jpn J Ophthalmol. 2008 Mar-Apr. 52(2):136-8. [Medline].

Elston DM, Ferringer T, Ko C, Peckham S, High W, DiCaudo D. Dermatopathology. 2nd ed. Philadelphia, Pa: Elsevier Saunders; 2013.

[Guideline] Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May. 58(5):826-50. [Medline].

[Guideline] Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009 Apr. 60(4):643-59. [Medline].

[Guideline] Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010 Jan. 62(1):114-35. [Medline].

[Guideline] Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Feb 7. [Medline].

Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2009 Apr 15. CD005028. [Medline].

Stern RS. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: A 30-year prospective study. J Am Acad Dermatol. 2012 Jan 18. [Medline].

Carrascosa JM, Plana A, Ferrandiz C. Effectiveness and Safety of Psoralen-UVA (PUVA) Topical Therapy in Palmoplantar Psoriasis: A Report on 48 Patients. Actas Dermosifiliogr. 2013 Mar 6. [Medline].

Mehta D, Lim HW. Ultraviolet B Phototherapy for Psoriasis: Review of Practical Guidelines. Am J Clin Dermatol. 2016 Feb 12. [Medline].

Stern DK, Creasey AA, Quijije J, Lebwohl MG. UV-A and UV-B Penetration of Normal Human Cadaveric Fingernail Plate. Arch Dermatol. 2011 Apr. 147(4):439-41. [Medline].

Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. Int J Mol Sci. 2016 Feb 5. 17 (2):[Medline].

Salvi M, Macaluso L, Luci C, Mattozzi C, Paolino G, Aprea Y, et al. Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C. World J Clin Cases. 2016 Feb 16. 4 (2):49-55. [Medline].

Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, et al. Autoimmune Diseases and Myelodysplastic Syndromes. Am J Hematol. 2016 Feb 13. [Medline].

Sorensen EP, Algzlan H, Au SC, Garber C, Fanucci K, Nguyen MB, et al. Lower Socioeconomic Status is Associated With Decreased Therapeutic Response to the Biologic Agents in Psoriasis Patients. J Drugs Dermatol. 2016 Feb 1. 15 (2):147-53. [Medline].

Castaldo G, Galdo G, Rotondi Aufiero F, Cereda E. Very low-calorie ketogenic diet may allow restoring response to systemic therapy in relapsing plaque psoriasis. Obes Res Clin Pract. 2015 Nov 8. [Medline].

Barrea L, Balato N, Di Somma C, Macchia PE, Napolitano M, Savanelli MC, et al. Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?. J Transl Med. 2015 Jan 27. 13:18. [Medline].

Millsop JW, Bhatia BK, Debbaneh M, Koo J, Liao W. Diet and psoriasis, part III: role of nutritional supplements. J Am Acad Dermatol. 2014 Sep. 71 (3):561-9. [Medline].

levering minocin antibiotic